September 24th 2024
During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses combination therapy with nivolumab plus ipilimumab and chemotherapy for patients with non–small cell lung cancer in the first article of a 2-part series.
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Frontline Pembrolizumab Combo Granted Priority Review by FDA for NSCLC
January 11th 2017A supplemental biologics license application for pembrolizumab in combination with pemetrexed plus carboplatin has been granted priority review by the FDA as a treatment for patients with metastatic or advanced non-squamous non–small cell lung cancer without <em>EGFR</em> or <em>ALK</em> mutations and regardless of PD-L1 expression.
Read More
Expert Discusses Determining Lung Cancer Treatments Using PD-L1 Expression
January 10th 2017PD-L1 expression is starting to be part of the standard of care in determining the appropriate treatment plan for newly diagnosed non-small cell lung cancer. However, testing for the biomarker is not always necessary for patients who have relapsed or who have small cell lung cancer.
Read More
Prolonged PFS From Addition of Ipilimumab to Nivolumab in Advanced NSCLC
December 16th 2016Findings from an efficacy update of patients participating in a study in the CheckMate series revealed that first-line nivolumab (Opdivo) demonstrated activity in advanced non–small cell lung cancer, and the addition of ipilimumab (Yervoy) resulted in enhanced activity, specifically in prolonged progression-free survival and higher objective response rates.
Read More
Response to Durvalumab Increased With High PD-L1 Expression in Pretreated NSCLC
December 16th 2016Durvalumab treatment in the second-line setting or beyond demonstrated clinical benefit and led to durable responses in heavily pretreated patients with locally advanced or metastatic non-small cell lung cancer.
Read More
France Takes Step Toward Standardizing PD-L1 Immunohistochemistry Testing
December 13th 2016Determining the PD-L1 status of a patient’s tumor has become increasingly important for informing the clinical decision whether to offer certain immunotherapeutic agents, making standardization of the tests and antibodies used to determine the PD-L1 status necessary to provide accurate and consistent results.
Read More
Osimertinib Greatly Reduces Disease Progression Risk in EGFR T790M-Mutant NSCLC
December 8th 2016Osimertinib (Tagrisso) reduced the risk of disease progression by 70% compared with a chemotherapy doublet in patients with EGFR T790M-mutant non–small cell lung cancer (NSCLC) who progressed after first-line targeted therapy, according to phase III clinical trial results.
Read More
KEYNOTE-010 Shows Overall Survival Benefit of Pembrolizumab in NSCLC
December 8th 2016Roy. S. Herbst, MD, PhD, professor of Medicine (Medical Oncology), professor of Pharmacology, chief of Medical Oncology, Yale Cancer Center, discusses the phase III KEYNOTE-010 study, in which pembrolizumab provided superior overall survival over docetaxel in patients with previously treated, PD-L1-expressing advanced non-small cell lung cancer. He discussed these results during an interview at the IASLC 17th World Conference on Lung Cancer.
Watch
The Benefits of myPlan to Help Identify High-Risk Patients With NSCLC
November 24th 2016Jeffrey Schneider, MD, chief of hematology and medical oncology, Winthrop University Hospital, discusses the benefits of Myriad's myPlan in determining high-risk patients with non-small cell lung cancer (NSCLC).
Watch
Little Quality-of-Life Benefit Seen When Whole-Brain Radiotherapy Administered in NSCLC
November 18th 2016Patients with non-small cell lung cancer whose disease has metastasized to the brain can do without whole-brain radiotherapy, according to a study published in <em>Lancet.</em>
Read More
Erlotinib Plus Bevacizumab in EGFR-Mutant NSCLC
November 18th 2016Howard L. “Jack” West, MD, thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses the combination of erlotinib plus bevacizumab (Avastin) as a frontline treatment for patients with unresectable advanced, metastatic, or recurrent <em>EGFR</em>-mutant non-small cell lung cancer (NSCLC).
Watch
Erlotinib/Bevacizumab Combo Warrants Consideration for EGFR+ NSCLC
November 17th 2016The promising clinical efficacy seen with the combination of erlotinib and bevacizumab as a treatment for patients with <em>EGFR</em>-mutant non–small cell lung cancer warrants widespread consideration.
Read More
Addressing the Challenges of Treating Non-Driver NSCLC
November 15th 2016Targeted therapies have revolutionized the treatment of patients with non–small cell lung cancer; however, not all patients harbor identifiable driver mutations. Standard treatment options among patients lacking molecular targets include chemotherapy and antiangiogenesis agents.
Read More